Thomson Reuters Announces Pricing of Public Offering of US$1,300,000,000 Notes and Canadian Private Placement of C$1,000,000,000 Notes

Thomson Reuters priced US$1.3 billion of U.S. notes and C$1.0 billion of Canadian notes, for aggregate gross issuance of roughly US$2.0 billion equivalent across maturities from 2028 to 2033. The debt includes US$800 million of 5.10% 2028 notes, US$500 million of 5.75% 2033 notes, C$700 million of fixed-rate notes, and C$300 million of CORRA+76bp floating-rate notes. Net proceeds of approximately US$1.295 billion and C$997 million will fund general corporate purposes, including repayment of commercial-paper borrowings; closing is expected September 17, 2026.

Analysis

This is primarily a balance-sheet signal, not an equity catalyst. Refinancing commercial paper with termed debt reduces rollover exposure and locks a meaningful portion of funding costs, but the all-in coupons imply that incremental leverage is no longer essentially free; absent an identifiable acquisition or accelerated capital-return program, TRI's equity multiple should not expand on this issuance alone. The mixed USD/CAD and fixed/floating structure also limits near-term rate and currency mismatch, leaving execution risk low once the transaction closes.

The actionable read is in TRI's next earnings materials: net debt/EBITDA, interest expense guidance, commercial-paper balance, and the use of proceeds beyond repayment determine whether this is defensive liability management or pre-funding for M&A. In the next 1-3 months, a material rise in net leverage without a disclosed high-return deployment would modestly pressure free-cash-flow conversion and make TRI more vulnerable to valuation derating versus asset-light information-services peers such as BR and NDAQ. Over 6-18 months, an acquisition funded partly through this raise could be strategically positive only if recurring-revenue retention and cost synergies offset the higher funding hurdle.

Contrarian view: the equity market may interpret a large multi-currency deal as acquisition preparation, but management's stated use is broad and debt repayment is explicitly included. Until a target, purchase price, and financing mix are disclosed, there is no basis to capitalize synergies or assign M&A upside; the cleaner inference is improved liquidity with a modest recurring interest-cost headwind. A sharp widening in TRI credit spreads after pricing, or a cut to FCF guidance at the next results, would falsify the benign-refinancing thesis.

Key Decisions for Investors

• No standalone equity trade on the financing announcement; maintain TRI at benchmark weight through the September 17 closing and reassess at the next earnings release, when the commercial-paper reduction and pro forma net leverage should be disclosed.
• Set an alert for TRI net debt/EBITDA rising by more than 0.5x versus the prior quarter without a disclosed acquisition or incremental EBITDA contribution; that outcome supports a 1-3 month TRI underweight versus BR, where the valuation risk is leverage-driven rather than operational.
• For credit portfolios, monitor secondary pricing of the new 2033 USD notes versus TRI's existing curve and comparable BBB information-services issuers. A spread concession exceeding roughly 20-25 bp after settlement would indicate absorption risk and justify waiting rather than adding duration.
• Treat any announced acquisition within six months as a separate event trade: only consider adding TRI if management demonstrates a post-synergy return above the roughly 5%-6% marginal debt cost and maintains FCF guidance; otherwise favor a short TRI/long BR relative-value position.